About
Pipeline
For patients & physicians
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Pipeline
Pipeline overview
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
TILVESTAMAB (BGB149)
Publications
For patients & physicians
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Rights Issue 2023
Warrants
Contact us
Developing breakthrough AXL therapeutics to improve patients' lives
D
e
v
e
l
o
p
i
n
g
b
r
e
a
k
t
h
r
o
u
g
h
A
X
L
t
h
e
r
a
p
e
u
t
i
c
s
t
o
i
m
p
r
o
v
e
p
a
t
i
e
n
t
s
'
l
i
v
e
s
Learn About Us
Information about the Warrants
Read more
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
30th April 2024
BerGenBio ASA: Notice of Annual General Meeting
Read more
30th April 2024
BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023
Read more
25th April 2024
BerGenBio ASA: New share capital registered
Read more
17th April 2024
BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission
Read more
16th April 2024
BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue
Read more
15th April 2024
BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates
Read more
15th April 2024
BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue
Read more
8th April 2024
BerGenBio ASA: Last day of trading in warrants
Read more
3rd April 2024
BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue
Read more
All news
